TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
Promising Outlook and Attractive Entry Point: Josh Jennings' Buy Rating on TransMedics Group
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $180
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Collegium Pharmaceutical (COLL) and Korro Bio (KRRO)
TransMedics Group Is Maintained at Overweight by Piper Sandler
TransMedics Gr Analyst Ratings
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $180
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)
Morgan Stanley Maintains TransMedics(TMDX.US) With Hold Rating, Maintains Target Price $153
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
TransMedics Group (TMDX) Buy Rating Affirmed Amid Rising Market Share and Competitive Edge
Baird Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $200
TransMedics Gr Analyst Ratings
Baird Initiates Coverage On TransMedics Gr With Outperform Rating, Announces Price Target of $200
Baird Initiates TransMedics(TMDX.US) With Buy Rating, Announces Target Price $200
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Raises Target Price to $180
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $200
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $200
Needham Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $208